| A randomized trial of bevacizumab for newly diagnosed glioblastoma MR Gilbert, JJ Dignam, TS Armstrong, JS Wefel, DT Blumenthal, ... New England Journal of Medicine 370 (8), 699-708, 2014 | 3161 | 2014 |
| Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial MR Gilbert, M Wang, KD Aldape, R Stupp, ME Hegi, KA Jaeckle, ... Journal of clinical oncology 31 (32), 4085-4091, 2013 | 1165 | 2013 |
| Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial M Weller, N Butowski, DD Tran, LD Recht, M Lim, H Hirte, L Ashby, ... The lancet oncology 18 (10), 1373-1385, 2017 | 1071 | 2017 |
| Clinical analysis of anti-Ma2-associated encephalitis J Dalmau, F Graus, A Villarejo, JB Posner, D Blumenthal, B Thiessen, ... Brain 127 (8), 1831-1844, 2004 | 847 | 2004 |
| Vorasidenib in IDH1-or IDH2-mutant low-grade glioma IK Mellinghoff, MJ Van Den Bent, DT Blumenthal, M Touat, KB Peters, ... New England Journal of Medicine 389 (7), 589-601, 2023 | 368 | 2023 |
| An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825 H Gittleman, D Lim, MW Kattan, A Chakravarti, MR Gilbert, AB Lassman, ... Neuro-oncology 19 (5), 669-677, 2017 | 209 | 2017 |
| Treatment with bevacizumab and irinotecan for recurrent high‐grade glial tumors F Bokstein, S Shpigel, DT Blumenthal Cancer 112 (10), 2267-2273, 2008 | 191 | 2008 |
| Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG DT Blumenthal, T Gorlia, MR Gilbert, MM Kim, L Burt Nabors, WP Mason, ... Neuro-oncology 19 (8), 1119-1126, 2017 | 167 | 2017 |
| Neurologic complications of immune checkpoint inhibitors A Fellner, C Makranz, M Lotem, F Bokstein, A Taliansky, S Rosenberg, ... Journal of neuro-oncology 137, 601-609, 2018 | 159 | 2018 |
| RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). MR Gilbert, M Wang, KD Aldape, R Stupp, M Hegi, KA Jaeckle, ... Journal of Clinical Oncology 29 (15_suppl), 2006-2006, 2011 | 155 | 2011 |
| Short delay in initiation of radiotherapy may not affect outcome of patients with glioblastoma: a secondary analysis from the radiation therapy oncology group database DT Blumenthal, M Won, MP Mehta, WJ Curran, L Souhami, JM Michalski, ... Journal of clinical oncology 27 (5), 733-739, 2009 | 149 | 2009 |
| RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). MR Gilbert, J Dignam, M Won, DT Blumenthal, MA Vogelbaum, ... Journal of Clinical Oncology 31 (18_suppl), 1-1, 2013 | 147 | 2013 |
| Congenital partial aplasia of the posterior arch of the atlas causing myelopathy: case report and review of the literature P Klimo Jr, DT Blumenthal, WT Couldwell Spine 28 (12), E224-E228, 2003 | 118 | 2003 |
| Acute type II myofiber atrophy in critical illness L Gutmann, D Blumenthal, L Gutmann, SS Schochet Neurology 46 (3), 819-821, 1996 | 114 | 1996 |
| Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency A Das, S Sudhaman, D Morgenstern, A Coblentz, J Chung, SC Stone, ... Nature medicine 28 (1), 125-135, 2022 | 113 | 2022 |
| Capecitabine-induced multifocal leukoencephalopathy: a report of five cases A Videnovic, I Semenov, R Chua-Adajar, L Baddi, DT Blumenthal, ... Neurology 65 (11), 1792-1794, 2005 | 101 | 2005 |
| Primary intracranial neoplasms in patients with HIV DT Blumenthal, JJ Raizer, MK Rosenblum, MH Bilsky, S Hariharan, ... Neurology 52 (8), 1648-1648, 1999 | 101 | 1999 |
| Molecular-based recursive partitioning analysis model for glioblastoma in the temozolomide era: a correlative analysis based on NRG oncology RTOG 0525 EH Bell, SL Pugh, JP McElroy, MR Gilbert, M Mehta, AC Klimowicz, ... JAMA oncology 3 (6), 784-792, 2017 | 99 | 2017 |
| Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors DT Blumenthal, M Yalon, GW Vainer, A Lossos, S Yust, L Tzach, ... Journal of neuro-oncology 129, 453-460, 2016 | 95 | 2016 |
| Delayed contrast extravasation MRI: a new paradigm in neuro-oncology L Zach, D Guez, D Last, D Daniels, Y Grober, O Nissim, C Hoffmann, ... Neuro-oncology 17 (3), 457-465, 2015 | 93 | 2015 |
